Biodesix, Inc. (BDSX)
| Market Cap | 99.80M +56.8% |
| Revenue (ttm) | 105.21M +31.2% |
| Net Income | -27.08M |
| EPS | -2.80 |
| Shares Out | 11.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 258,903 |
| Open | 9.86 |
| Previous Close | 9.88 |
| Day's Range | 8.89 - 9.86 |
| 52-Week Range | 5.26 - 31.97 |
| Beta | 0.63 |
| Analysts | Strong Buy |
| Price Target | 32.17 (+257.44%) |
| Earnings Date | Nov 5, 2026 |
About BDSX
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to... [Read more]
Financial Performance
In 2025, Biodesix's revenue was $88.50 million, an increase of 24.08% compared to the previous year's $71.32 million. Losses were -$35.27 million, -17.86% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for BDSX stock is "Strong Buy." The 12-month stock price target is $32.17, which is an increase of 257.44% from the latest price.
News
Biodesix (BDSX) Shares Plunge; Johnson Fistel's Colorado Office Initiates Investigation on Behalf of Investors
SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a national shareholder rights law firm with an office in Denver, Colorado, has begun investigating potential securities claims on beh...
Biodesix (BDSX) Shares Plunge; Johnson Fistel's Colorado Office Initiates Investigation on Behalf of Investors
SAN DIEGO, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a national shareholder rights law firm with an office in Denver, Colorado, has begun investigating potential securities claims on beh...
Biodesix Transcript: UBS Global Healthcare Conference
Q3 testing revenue grew 16% YoY, but lower sales capacity and primary-care seasonality weighed on performance; October trends improved. Priorities include rebuilding commercial capacity, automating care pathways, advancing digital diagnostics and reaching profitability by end-2027.
Biodesix price target lowered to $34 from $38 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Biodesix (BDSX) to $34 from $38 and keeps a Buy rating on the shares. The company reported a sales…
Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting
New data highlighting proprietary bioinformatics, ultrasensitive molecular detection, and collaborations with Bio-Rad Laboratories and Thermo Fisher Scientific to advance scalable MRD solutions for cl...
Biodesix price target lowered to $30 from $40 at Lake Street
Lake Street lowered the firm’s price target on Biodesix (BDSX) to $30 from $40 and keeps a Buy rating on the shares. Biodesix reported Q3 revenue that missed the firm’s…
Biodesix price target lowered to $34 from $40 at TD Cowen
TD Cowen lowered the firm’s price target on Biodesix (BDSX) to $34 from $40 and keeps a Buy rating on the shares. The firm updated its model following Q3 results…
Biodesix sees FY26 revenue $101M-$103M, consensus $111.82M
Sees gross margins of approximately 80%.
Biodesix reports Q3 EPS (75c) vs. ($1.16) last year
Reports Q3 revenue $24.0M, consensus $27.49M. Diagnostic Testing revenue grew 16% year-over-year with test volumes up 24%, while gross margin remained flat at 81%. “Biodesix (BDSX) delivered another q...
Biodesix Earnings Call Transcript: Q3 2026
Q3 revenue rose 10% and test volumes 24%, but staffing gaps, primary-care seasonality, and delayed projects weighed on results. FY 2026 revenue guidance is $101M–$103M, while health-system integrations and diagnostic programs support longer-term growth.
Biodesix Earnings release: Q3 2026
Biodesix released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Biodesix Quarterly report: Q3 2026
Biodesix has published its Q3 2026 quarterly earnings report on November 5, 2026.
Biodesix Announces Third Quarter 2026 Results and Highlights
Delivered total revenue of $24.0 million, an increase of 10% year over year Grew Diagnostic Testing revenue 16% year over year, with test volumes increasing 24% Maintained an 81% gross margin, improve...
Biodesix to Participate in Upcoming Investor Conferences
LOUISVILLE, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present a...
Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026
LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter...
American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification
New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices New CHEST framework developed by a re...
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers
Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment Partnership with Vanderbilt University and Vander...
Biodesix price target raised to $40 from $30 at TD Cowen
TD Cowen raised the firm’s price target on Biodesix (BDSX) to $40 from $30 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics space…
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing New sponsored and independent research evaluates clinical utility, patient follow-u...
Biodesix price target raised to $38 from $27 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Biodesix (BDSX) to $38 from $27 and keeps a Buy rating on the shares. The company’s new tumor-informed and tumor-naive Molecular Residual…
Biodesix advances two programs for Molecular Residual Disease monitoring
Biodesix (BDSX) announced strategic progress in two collaborative programs for tumor-informed and tumor-naive Molecular Residual Disease – or MRD – solutions intended to support cancer centers and cli...
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise Biodesix-led tumor-informed and tumor-naïve programs draw on the co...
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates ...
Biodesix Transcript: Canaccord Genuity's 46th Annual Growth Conference
Strong sales force expansion and clinical evidence are driving robust revenue growth and high gross margins. The company is focused on profitability, pipeline development, and leveraging its infrastructure for future opportunities, with major updates expected at the AMP meeting.
Biodesix price target raised to $35 from $27 at Canaccord
Canaccord raised the firm’s price target on Biodesix (BDSX) to $35 from $27 and keeps a Buy rating on the shares. The firm said they the company reported 2Q26 results…